- Home
- SGML vs ANIP Comparison
SGML vs ANIP Comparison
Compare SGML & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGML
- ANIP
- Stock Information
- Founded
- SGML 2011
- ANIP 2001
- Country
- SGML Brazil
- ANIP United States
- Employees
- SGML N/A
- ANIP N/A
- Industry
- SGML Industrial Machinery/Components
- ANIP Biotechnology: Pharmaceutical Preparations
- Sector
- SGML Industrials
- ANIP Health Care
- Exchange
- SGML Nasdaq
- ANIP Nasdaq
- Market Cap
- SGML 879.0M
- ANIP 1.5B
- IPO Year
- SGML N/A
- ANIP N/A
- Fundamental
- Price
- SGML $7.42
- ANIP $71.53
- Analyst Decision
- SGML Strong Buy
- ANIP Strong Buy
- Analyst Count
- SGML 2
- ANIP 8
- Target Price
- SGML $18.00
- ANIP $80.13
- AVG Volume (30 Days)
- SGML 815.2K
- ANIP 387.2K
- Earning Date
- SGML 05-14-2025
- ANIP 05-09-2025
- Dividend Yield
- SGML N/A
- ANIP N/A
- EPS Growth
- SGML N/A
- ANIP N/A
- EPS
- SGML N/A
- ANIP N/A
- Revenue
- SGML $145,080,064.00
- ANIP $614,376,000.00
- Revenue This Year
- SGML $43.73
- ANIP $27.68
- Revenue Next Year
- SGML $130.53
- ANIP $7.74
- P/E Ratio
- SGML N/A
- ANIP N/A
- Revenue Growth
- SGML 15.18
- ANIP 26.20
- 52 Week Low
- SGML $6.76
- ANIP $52.50
- 52 Week High
- SGML $19.20
- ANIP $73.72
- Technical
- Relative Strength Index (RSI)
- SGML 38.86
- ANIP 59.87
- Support Level
- SGML $6.81
- ANIP $68.50
- Resistance Level
- SGML $8.40
- ANIP $73.72
- Average True Range (ATR)
- SGML 0.47
- ANIP 2.29
- MACD
- SGML 0.04
- ANIP -0.08
- Stochastic Oscillator
- SGML 36.97
- ANIP 64.22
About SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About ANIP ANI Pharmaceuticals Inc.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.